The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Novel treatment approaches in pancreatic cancer therapy
Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, provides an overview of innovative strategies in the treatment of pancreatic cancer. Despite the introduction of liposomal irinotecan and recent findings from the Phase III NAPOLI-3 trial (NCT04083235), survival rates have not drastically improved over the past decade. Dr Weinberg additionally highlights the need to find new targets and actionable subtypes of pancreatic cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
